Finance Watch: Two SPAC Deals, Two IPOs Take Four Biopharmas Public

Surrozen Merging With Consonance-HFW Acquisition, Raising $212m

Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.

Finance Watch

Surrozen Inc. is raising $212m in 2021 as it prepares to enter the clinic in 2022, going public through a merger with the special purpose acquisition corporation (SPAC) Consonance-HFW Acquisition Corp. Surrozen, which is focused on tissue repair and regeneration through selective activation of the Wnt pathway, will garner $92m held in trust by the SPAC when the merger closes and raise $120m from a concurrent private investment in public equity (PIPE) financing.

The Surrozen/Consonance-HFW merger announced on 15 April was the second SPAC merger unveiled by a preclinical biopharmaceutical company in two days; on 14 April, Tango Therapeutics, Inc. revealed its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Finance Watch

Finance Watch: Public Company Fundraising Sank Across The Board In Q1

 
• By 

Public Company Edition: Biomedtracker’s first quarter 2025 financing report shows follow-on offerings, IPOs and PIPEs fell sharply from Q1 of 2024. In recent transactions, Teva sold $2.3bn worth of notes, Regenxbio executed a royalty deal for up to $250m and Aura’s FOPO grossed $75m.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By 

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts

 
• By 

Restructuring Edition: Prime Medicine ended its sole clinical-stage program to prioritize preclinical and partnered programs, cutting 25% of its workforce to extend its cash runway. Meanwhile, earnings season brought workforce reductions at Kyverna, Allogene, Leap and others.

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

 
• By 

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

More from Financing

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts

 
• By 

Restructuring Edition: Prime Medicine ended its sole clinical-stage program to prioritize preclinical and partnered programs, cutting 25% of its workforce to extend its cash runway. Meanwhile, earnings season brought workforce reductions at Kyverna, Allogene, Leap and others.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By 

The German biotech has been forced into insolvency and NASDAQ suspension.

Hengrui Set For Biggest Biopharma IPO So Far This Year

 

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.